This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chlenski, A. Articles by Cohn, S. L. Search for Related Content PubMed PubMed Citation Articles by Chlenski, A. Articles by Cohn, S. L.

Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC

¹ The Robert H. Lurie Comprehensive Cancer Center and ² Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois

Secreted protein acidic and rich in cysteine (SPARC) is a multifunctional matricellular glycoprotein. In vitro, SPARC inhibits the proliferation and migration of endothelial cells stimulated by growth factors and induces endothelial cell apoptosis. We previously showed that SPARC also inhibits angiogenesis in vivo and impairs the growth of the pediatric tumor neuroblastoma (NB). SPARC comprises three domains that are independently folded by a complex pattern of disulfide bonds and have a high degree of structural conservation. In this study, separate modules of the SPARC domains were synthesized as cysteine-linked peptides and tested for their ability to inhibit angiogenesis. Peptide FS-E, representing the epidermal growth factor (EGF)-like module of the follistatin (FS) domain, did not cause endothelial cell apoptosis but strongly inhibited basic fibroblast growth factor (bFGF)–induced endothelial cell migration with an ED₅₀ = 10 pmol/L. In vivo, peptide FS-E blocked bFGF-stimulated angiogenesis and neovascularization induced by NB cells. The EGF-like conformation was essential for peptide FS-E function because reduction of its two disulfide bonds completely abrogated peptide activity. Peptides FS-K and EC-N, corresponding to part of the Kazal module of the FS domain and the conserved -helix in the extracellular calcium-binding domain, respectively, had minimal to no inhibitory activity. Our data show that the EGF-like module of the SPARC FS domain is angiosuppressive, and its structural conformation is critical for antiangiogenic activity.

This article has been cited by other articles:

				A. M. Orimoto, K. Dumaresq-Doiron, J.-Y. Jiang, N. Tanphaichitr, B. K. Tsang, and E. Carmona Mammalian Hyaluronidase Induces Ovarian Granulosa Cell Apoptosis and Is Involved in Follicular Atresia Endocrinology, November 1, 2008; 149(11): 5835 - 5847. [Abstract] [Full Text] [PDF]

				N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed Normalization of the Ovarian Cancer Microenvironment by SPARC Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030. [Abstract] [Full Text] [PDF]

				E. F. Rocnik, P. Liu, K. Sato, K. Walsh, and C. Vaziri The Novel SPARC Family Member SMOC-2 Potentiates Angiogenic Growth Factor Activity J. Biol. Chem., August 11, 2006; 281(32): 22855 - 22864. [Abstract] [Full Text] [PDF]

				S. Jodele, C. F. Chantrain, L. Blavier, C. Lutzko, G. M. Crooks, H. Shimada, L. M. Coussens, and Y. A. DeClerck The Contribution of Bone Marrow-Derived Cells to the Tumor Vasculature in Neuroblastoma Is Matrix Metalloproteinase-9 Dependent Cancer Res., April 15, 2005; 65(8): 3200 - 3208. [Abstract] [Full Text] [PDF]